dr-p

1 Comment

    • China ADRs: Severe Loss in June [view article]
      Thanks to stockaccumulator for his excellent analysis of Renesolar. Similar may be said about Wuxi Pharmatech. WX is already one of the largest research partners for the global pharmaceutical industry and analyst do not seem to understand this company. The rational for pouring business into Wuxi is simple: Why would you want to spend 80-100k per year for a scientist in the US if you can have the same job done for less than half at Wuxi? Such FTE costs are not tenable in the long-term for US companies, and with the risk involved in drug development FTE's are even more costly if you rapidly have to cut jobs due to restructuring if projects fail. The brains need to be here, the hands can be at Wuxi. Working in the pharmaceutical industry myself I know that their reputation is excellent, and so is their service. Many of their scientists have been trained in the United States and quality of work is 100% of what is being achieved in this country. With Big-Pharma moving research activities to Asia (GSK for example operates centers of excellence in Singapore and Shanghai) and job-cuts in the US and Europe this company is only going to expand more rapidly. And be sure - this is NOT a biotech. Their operations are comparatively low risk with high growth. It is contract research and development. Service for fee. There is an additional advantage: Wuxi can help achieve compliance with regulatory requirements in China. The latter will be key to development of this vast market for current and new medicines. In my humble opinion, WX trading below their IPO price is a joke. Jul 04 12:24 PM
Loading...
Symbols:
Authors:
Quick Links:
Contribute an Article Become a Seeking Alpha Contributor

Transcripts

More Transcripts»

Trading Center